TESAMORELIN - 5mg

Tesamorelin supplied strictly for laboratory and scientific research purposes. This product is intended for in‑vitro and analytical research only. Not for human or veterinary use. Not a drug, supplement, or food product. All materials are provided as laboratory research chemicals and are not intended for consumption, injection, or medical use.
Tesamorelin is a synthetic growth hormone‑releasing hormone (GHRH) analog developed to stimulate endogenous growth hormone (GH) secretion from the pituitary gland. Clinically approved for the reduction of visceral adipose tissue (VAT) in patients with HIV‑associated lipodystrophy, Tesamorelin is also used in wellness and longevity research for fat loss, metabolic regulation, and body‑composition support.

By enhancing natural GH release, Tesamorelin helps target abdominal fat, improve lipid metabolism, and support overall metabolic balance, making it one of the most studied peptides for targeted fat reduction in human models.

Key Features

🧪 cGMP manufactured in an FDA‑registered facility
✅ ≥98% purity confirmed by HPLC analysis
📄 Batch‑specific Certificates of Analysis (COAs) included
💉 Sterile, lyophilized vials for research use only

Human‑Relevant Research Applications

🔥 Visceral fat reduction in humans
In clinical randomized trials, Tesamorelin significantly reduces visceral adipose tissue (VAT) — the metabolically active belly fat — compared with placebo over 6 months in adults with central fat accumulation.
🔗 https://pubmed.ncbi.nlm.nih.gov/20101189/

📉 Improved body composition & metabolic markers
Meta‑analyses show Tesamorelin reduces VAT and trunk fat, improves lipid profiles, and increases lean body mass without adverse impacts on glucose homeostasis in human subjects.
🔗 https://pubmed.ncbi.nlm.nih.gov/41545261/

💪 Sustained effects with continued treatment
Phase III clinical data demonstrate that VAT reductions are maintained with ongoing Tesamorelin use up to 52 weeks, with associated improvements in triglycerides and waist circumference.
🔗 https://pubmed.ncbi.nlm.nih.gov/20554713/

Mechanism Summary

• Stimulates growth hormone‑releasing hormone (GHRH) receptors in the anterior pituitary

• Promotes pulsatile secretion of endogenous growth hormone

• Increases IGF‑1 levels, which mediate fat metabolism and tissue maintenance

• Targets visceral adiposity more than subcutaneous fat via GH‑driven lipolytic signaling

Reconstitution & Handling Guidance

1️⃣ Use sterile bacteriostatic water (0.9% benzyl alcohol)
2️⃣ Add 3 ml of bacteriostatic water for peptide reconstitution
3️⃣ Gently swirl — do not vortex — until fully dissolved
4️⃣ Store reconstituted vial at 4 °C–10 °C for 2–3 months
5️⃣ Unreconstituted vials remain stable until expiry at 4 °C–10 °C

Frequently Asked Research Questions

How does Tesamorelin differ from direct GH injection?
Tesamorelin stimulates natural GH secretion by activating GHRH pathways, preserving physiological pulsatility and feedback mechanisms, unlike continuous GH dosing.

Does Tesamorelin influence subcutaneous fat?
Clinical studies show the most pronounced effects are on visceral adipose tissue, with minimal change in subcutaneous fat — reflecting targeted fat‑metabolism pathways.

Legal & Research Disclaimer

This material is supplied exclusively for laboratory research use. It is not intended for diagnostic, therapeutic, cosmetic, human, or veterinary applications. The purchaser assumes all responsibility for compliance with applicable local, state, and federal regulations governing research compounds.

هذا المنتج مخصص للاستخدام البحثي والمخبري فقط، وغير مخصص للاستخدام البشري أو الحيواني.

⚠️ Important Notice
This product is intended strictly for laboratory research use only.
Not for human use, medical, or veterinary purposes.
No clinical or dosage advice will be provided.